Telix Pharmaceuticals has entered an agreement to add Subtle Medical’s AI software for enhancing prostate-specific membrane antigen (PSMA) PET prostate cancer scans to its product portfolio.
SubtlePET is a U.S. Food and Drug Administration (FDA) cleared deep-learning algorithm designed to enhance the efficiency and effectiveness of imaging procedures, Telix said. The algorithm allows for faster PET scanning, up to 75% faster without compromising image quality, according to the company.
Telix’s leading PSMA-PET imaging kit, Illucix, is used to perform gallium-68 PSMA-11 imaging exams in men with prostate cancer. The partnership covers North America and the European Union (excluding France and French speaking Belgium), the company said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
